# S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

> **NCT06188702** · PHASE1,PHASE2 · RECRUITING · sponsor: **Servier Bio-Innovation LLC** · enrollment: 342 (estimated)

## Conditions studied

- MTAP-deleted Solid Tumors

## Interventions

- **DRUG:** S095035
- **DRUG:** TNG462

## Key facts

- **NCT ID:** NCT06188702
- **Lead sponsor:** Servier Bio-Innovation LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2031-10-31
- **Final completion:** 2031-10-31
- **Target enrollment:** 342 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06188702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06188702, "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06188702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*